Skip to main content

Table 1 RTOG studies included in analysis

From: The prognostic value of nestin expression in newly diagnosed glioblastoma: Report from the Radiation Therapy Oncology Group

Study

Phase

Description

N = 153

7401

III

WBRT+(BCNU vs. MeCCNU+DTIC)

38 (25%)

7918

III

WBRT+(BCNU vs. Misonidazole radiosensitizer & BCNU)

9 (6%)

8302

III

Hyperfractionated and Accelerated RT + BCNU

30 (20%)

8409

I/II

WBRT + AZQ (NSC-182986)

1 (1%)

9006

III

BCNU + (Hyperfractionated RT vs. RT)

32 (21%)

9305

III

+/-SRS followed by RT+BCNU

3 (2%)

9602

II

RT + Taxol

13 (8%)

9806

II

RT + Thalidomide

27 (18%)